# DESCRIPTION

## BACKGROUND OF THE INVENTION

- motivate molecularly targeted contrast agents

## SUMMARY OF THE INVENTION

- summarize methods and compositions
- describe phospholipid-ligand bioconjugates
- outline targeted microbubbles production

## DETAILED DESCRIPTION OF THE EMBODIMENTS OF THE INVENTION

- define scope of invention
- describe terminology used
- explain inert gas and mole percent
- define thiol-Michael addition reaction
- describe PEG and its structures
- define tumor, cancer, and neoplasia
- describe antibody and its forms
- explain B7-H3 and its structure
- describe diabody, affibody, and microbubble
- define therapeutically effective amount and treating

### Methods of Producing Phospholipid-Ligand Bioconjugates

- define phospholipid-ligand bioconjugate production method
- describe phospholipid polymer preparation
- specify ligand characteristics
- outline phospholipid-ligand contacting conditions
- describe phospholipid-ligand bioconjugate physical characteristics

### Methods of Producing Target Microbubbles

- define microbubbles
- describe production methods
- specify phospholipid liposomes
- detail targeted microbubbles conjugated to therapeutic molecules
- list therapeutic agents

### Methods of Treating Cancer

- introduce targeted microbubble conjugated to therapeutic molecule
- describe ligand specifically binding to protein on cancer cell surface
- list various cancer cells and therapeutic agents
- discuss dosage and frequency of administration
- describe carriers and formulations for administration
- mention combination therapy with additional therapeutic agents

### Compositions

- introduce compositions comprising phospholipid-ligand bioconjugates or targeted microbubbles
- describe pharmaceutically acceptable excipients and formulations

## EXPERIMENTAL

### Introduction

- motivate phospholipids-based microbubbles
- limitations of current targeted microbubbles
- introduce microfluidic-based processing methods

### Results

- present expression and target binding assessments of ABY ligands
- describe binding affinities to human/mouse B7-H3
- assess purities of ABYAC2 and ABYACI2 protein
- test binding efficiency of ABYAC2 and ABYAC12 to endothelial cell line
- characterize binding efficiency of ABY ligand to MDA-MB-231 human breast cancer cells
- test His-Tag removal from purified proteins
- optimize bioconjugation of ABY with Mal-phospholipids
- analyze stability of DSPE-PEG-ABY conjugates
- prepare targeted MBB7-H3 with DSPE-PEG-ABY
- validate binding of MBB7-H3 targeted to endothelial cells in vitro and in vivo

### Materials and Methods

- list reagents and chemicals
- describe cell culture
- outline protein modification, expression, and purification
- detail biotinylation of ABY
- describe His-Tag removal by enzymatic cleavage
- outline phospholipid-ligand bioconjugation
- describe flow cytometry analysis
- detail preparation of targeted microbubbles by a microfluidic system
- validate ABY display on targeted microbubbles

